Last reviewed · How we verify

Eurartesim dispersible oral tablet

sigma-tau i.f.r. S.p.A. · Phase 2 active Small molecule

Eurartesim dispersible oral tablet is a antimalarial Small molecule drug developed by sigma-tau i.f.r. S.p.A.. It is currently in Phase 2 development for Uncomplicated Plasmodium falciparum malaria. Also known as: Piperaquine tetraphosphate plus dihydroartemisinin.

Eurartesim is a fixed-dose combination of dihydroartemisinin and piperaquine, targeting the hemozoin formation in Plasmodium parasites to treat malaria.

Eurartesim is a fixed-dose combination of dihydroartemisinin and piperaquine, targeting the hemozoin formation in Plasmodium parasites to treat malaria. Used for Uncomplicated Plasmodium falciparum malaria.

At a glance

Generic nameEurartesim dispersible oral tablet
Also known asPiperaquine tetraphosphate plus dihydroartemisinin
Sponsorsigma-tau i.f.r. S.p.A.
Drug classantimalarial
Targethemozoin formation in Plasmodium parasites
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 2

Mechanism of action

Dihydroartemisinin rapidly kills the asexual blood stages of Plasmodium falciparum by disrupting hemozoin formation and inducing oxidative stress, while piperaquine provides longer-lasting prophylactic activity against the parasite.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Eurartesim dispersible oral tablet

What is Eurartesim dispersible oral tablet?

Eurartesim dispersible oral tablet is a antimalarial drug developed by sigma-tau i.f.r. S.p.A., indicated for Uncomplicated Plasmodium falciparum malaria.

How does Eurartesim dispersible oral tablet work?

Eurartesim is a fixed-dose combination of dihydroartemisinin and piperaquine, targeting the hemozoin formation in Plasmodium parasites to treat malaria.

What is Eurartesim dispersible oral tablet used for?

Eurartesim dispersible oral tablet is indicated for Uncomplicated Plasmodium falciparum malaria.

Who makes Eurartesim dispersible oral tablet?

Eurartesim dispersible oral tablet is developed by sigma-tau i.f.r. S.p.A. (see full sigma-tau i.f.r. S.p.A. pipeline at /company/sigma-tau-i-f-r-s-p-a).

Is Eurartesim dispersible oral tablet also known as anything else?

Eurartesim dispersible oral tablet is also known as Piperaquine tetraphosphate plus dihydroartemisinin.

What drug class is Eurartesim dispersible oral tablet in?

Eurartesim dispersible oral tablet belongs to the antimalarial class. See all antimalarial drugs at /class/antimalarial.

What development phase is Eurartesim dispersible oral tablet in?

Eurartesim dispersible oral tablet is in Phase 2.

What are the side effects of Eurartesim dispersible oral tablet?

Common side effects of Eurartesim dispersible oral tablet include headache, dizziness, nausea.

What does Eurartesim dispersible oral tablet target?

Eurartesim dispersible oral tablet targets hemozoin formation in Plasmodium parasites and is a antimalarial.

Related